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patients (pts). Although transport by the Emergency Medical Services (EMS)
is strongly recommended, other ways of transportation continue to be used. 
The aim of this analysis was to examine the evolution over time of the dif-
ferent ways of transport among the MIRAMI registry pts.
Methods and Results. From January 1995 to April 2011, 1353 pts were
enrolled in the the MIRAMI (MonastIR Acute Myocardial Infarction) registry.
Three ways of pre-hospital transport including self-transport, non medicalized
ambulance and EMS were used in our population. The use of theses ways over
time was analyzed on the 17 year – study period and shown in the figure
below: 
A significant (p=0.002) increase in the use of EMS was observed whereas
a proportion of approximately one third of the population continues to use a
self transport over the 17 year-study period. 
Conclusions. In our MIRAMI registry STEMI Patients transported by
EMS are significantly increasing during the last 17 years. However, approxi-
mately one third of these patients continue to use a self transport to get to the
hospital.
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Goal: 30 day and 1 year follow up of a STEMI population homogeneiously
treated with prehospital enoxaparin who underwent angioplasty.
Population and methods: 203 patients were included from june 2007 to
june 2008. 61 for the fibrinolysis group and 142 for the PPCI group. All
patients benefited of a clopidogrel loading dose (300 mg or 600 mg) and
aspirine (250 mg). Tenecteplase was the only fibrinolytic used. Enoxaparine
was given with a fixed intraveinous bolus (30 mg)and a subcutaneous dose 
(0,1 mk/kg). 30 day and 1 year data were obtained using data analysis or
phone call contact with patient, GP or cardiologist.
Results: 1 month mortality is 4,4% and 1 year mortality 5,9%. IIb/IIIa GPI
have 81%
prescription rate. There is no significant difference in term of events
between the PPCI group and the fibrinolysis group. Shock, severe bleedings,
longer ischemia times were predictive for events in the follow up.
Conclusion: On a « real life » STEMI population, enoxaparin use shows
very similar results to the one oberved in studies and registry with enoxaparin
use in term of ischemic and hemorragic events. Thus , our enoxaparin protocol
provide adequate anticoagulation simple to provide in pre hospitalary settings
indifferently of the reperfusion treatment realised.
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Background: Clopidogrel and low-dose aspirin have become the main-
stay oral antiplatelet regimen to prevent recurrent ischaemic events after
acute coronary syndromes or stent placement. The frequent genetic func-
tional variant 681 G>A (*2) of cytochrome P450 2C19 (CYP2C19) is an
important contributor to the wide variability between individuals of the anti-
platelet effect of clopidogrel. We assessed whether the CYP2C19*2 poly-
morphism affected long-term prognosis of patients who were chronically
treated with clopidogrel.
Methods: Between May 2009, and september 2010, 100 patients who
underwent a percutaneous coronary intervention (PCI) and were exposed to
clopidogrel treatment for at least one month, were enrolled in our study. They
underwent CYP2C19*2 determination. The primary endpoint was a composite
of death, myocardial infarction, and urgent coronary revascularisation occur-
ring during exposure to clopidogrel.
Results: Median clopidogrel exposure time was 6,67+/–6,38 months.
Baseline characteristics were balanced between carriers (heterozygous *1/*2,
n=23) and non-carriers (n=77) of CYP2C19*2 variant. The primary endpoint
occurred more frequently in carriers than in non-carriers (18,2% versus 5,3%
p=0·075). No significant differences were noted between the two groups
regarding the occurrence of stent thrombosis.
Conclusion. The CYP2C19*2 genetic variant is a major determinant of
prognosis in patients who are receiving clopidogrel treatment after PCI.
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Background: Food items might have a synergistic and antagonistic
effect on health. The Mediterranean diet has long been associated with
lower incidence of cardiovascular disease. Elevated blood homocysteine is
a risk factor for cardiovascular disease. Thiolactonase; the antioxidant
enzymatic component of HDL plays a crucial role in metabolizing homo-
cysteine thiolactone and reducing homocysteine endothelial damages.
Objective: A total of 53 elderly coronary artery disease patient were
recruited and divided into diabetic patient (n= 27; age= 68.3years) and non
diabetics (n=26; age= 68.7 years). We evaluated plasma homocysteine levels
(tHcy); thiolactonase activity (HTase) and studied the effects of adherence to
a Mediterranean diet on them.
Methods: tHcy was determined by a validated highly sensitive and accu-
rate capillary gas chromatography mass spectrometry method (GC-MS);
HTLase was estimated by a commercially available kit assay. Dietary intakes
were evaluated by a validated food frequency questionnaire 
Results: Significantly higher tHcy levels were found in diabetic patients as
compared to non diabetic (18.5 μmol/L (15-24) vs. 15.8 (14-17); p=0.05) asso-
ciated to lower HTase activities (266.8U/L (162-365) vs. 327.4 (240 –406);
p=0.05). Moreover, in the diabetic tHcy levels were negatively associated with
thiolactonase activities (r=–0.63; p- 0.00). In this group, Mediterranean diet
Results
